Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

Published:2024-05 Issue:5 Volume:11 Page:e285-e299
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Frank Ian,Li Shuying S,Grunenberg Nicole,Overton Edgar T,Robinson Samuel T,Zheng Hua,Seaton Kelly E,Heptinstall Jack R,Allen Mary A,Mayer Kenneth H,Culver Daniel A,Keefer Michael C,Edupuganti Sri,Pensiero Michael N,Mehra Vijay L,De Rosa Stephen C,Morris Daryl E,Wang Shixia,Seaman Michael S,Montefiori David C,Ferrari Guido,Tomaras Georgia D,Kublin James G,Corey Lawrence,Lu Shan

Funder

NIAID

Publisher

Elsevier BV

Reference31 articles.

1. Analysis of the HIV Vaccine Trials Network 702 phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk;Moodie;J Infect Dis,2022

2. Immune-correlates analysis of an HIV-1 vaccine efficacy trial;Haynes;N Engl J Med,2012

3. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination;Hollister;Hum Vaccin Immunother,2014

4. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans;Ugen;Vaccine,1998

5. Sequential immunization with gp140 boosts immune responses primed by modified vaccinia Ankara or DNA in HIV-uninfected South African participants;Churchyard;PLoS One,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotech's role in advancing HIV vaccine development;Emerging Microbes & Infections;2024-08-12

2. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains;Nature Communications;2024-05-21

3. DNA and protein HIV vaccines: how should we mix it?;The Lancet HIV;2024-05